0
Harpoon Therapeutics, Inc. Banner Image

Harpoon Therapeutics, Inc.

  • Ticker HARP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Harpoon Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in South San Francisco, California
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cellsMore. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2 trial in the second half of 2020.
Harpoon Therapeutics, Inc.

Most Recent Annual Report

Harpoon Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports